Scott Requadt - 29 Jul 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role
Chief Executive Officer, Director
Signature
/s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol
TRML
Transactions as of
29 Jul 2022
Net transactions value
+$167,374
Form type
4
Filing time
02 Aug 2022, 17:02:32 UTC
Previous filing
28 Jul 2022
Next filing
13 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TALS Common Stock Purchase $167,374 +39,382 +8.4% $4.25 508,680 29 Jul 2022 Direct
holding TALS Common Stock 449,766 29 Jul 2022 See Footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by Requadt Family Limited Partnership. The Reporting Person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.